NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT02557217
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Armaron Bio Pty Ltd
- Registry
-
NCT02557217 -
ACTRN12615000609550
-
- Other papers using this trial's data
- Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia
- Registry status
- Unknown status
Technical summary
Registry record NCT02557217. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
- Condition
- ST Elevation Myocardial Infarction
- Intervention (Drug)
- NP202
- Intervention (Other)
- Placebo
- Lead sponsor
- Armaron Bio Pty Ltd
Record details
- Record id
cardio:ct-nct02557217- Content hash
1cd2690efdbb55b4833f467837b8cdcb31c9e2463c1253b665d5b8534f3e1c06